FiercePharmaOriginal article
{"a":[{"_":"Samsung Bio, waiting to break into peptides, nets $262M manufacturing deal with unnamed EU pharma","$":{"href":"/manufacturing/samsung-bio-waiting-break-peptides-nets-262m-manufacturing-deal-unnamed-eu-pharma","hreflang":"en"}}]}
PartnershipPositive
AI Analysis
Summary
Samsung Biologics secured a $262M manufacturing deal with an unnamed European pharmaceutical company as it continues to pursue a major acquisition to expand into peptides production.
Financial Highlights
Revenue
$262M
Importance:6/10
Sentiment:
0.60
CDMOmanufacturingpeptidescontract manufacturingacquisition
Read the original article
Published by FiercePharma on September 10, 2026 7:40 AM